has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens recombinant vector vaccine subcutaneous route therapeutic vaccine function vaccine in clinical trial role recombinant vector vaccine role therapeutic cancer vaccine MVA-BN-CV301 vaccine Gene name: LFA-3 cancer vaccine Gene name: MUC1 Gene name: B7.1 941 3383 Gene name: ICAM-1 965 Jie Zheng VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6321 Gene name: CEA Hayleigh Kahn NCT: https://clinicaltrials.gov/study/NCT04574583 1048 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C143059 4582 6321 A cancer vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301 may lead to a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CV301 is a poxviral-based vaccine comprised of recombinant Modified vaccinia Ankara (MVA-BN-CV301, prime) and recombinant fowlpox (FPV-CV301, boost). CV301 contains transgenes encoding two (2) tumor-associated antigens (TAA), mucin 1 (MUC1) and carcinoembryonic antigen (CEA), as well as three costimulatory molecules (B7.1, intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function-associated antigen 3 (LFA-3), designated TRICOM). It is given in combination with SX-682 and M7824 for patients with Triple Negative Breast Cancer (TNBC) and Human papilloma virus (HPV) negative head and neck squamous cell carcinoma (HNSCC).